NYSE · MMS
Industrials · Specialty Business Services
$59.54
Up+$0.21 (+0.35%)
Updated Aug 28, 2026, 9:32 PM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MMS closed at $59.54 after 21 trading sessions, down 1.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $58.92 | $60.125 | $58.775 | $59.54 | 359.55K |
| Aug 26, 2026 | $58.15 | $59.265 | $57.82 | $58.97 | 364.4K |
| Aug 25, 2026 | $57.74 | $58.65 | $57.60 | $58.53 | 331.03K |
| Aug 24, 2026 | $58.20 | $58.71 | $58.01 | $58.24 | 345.86K |
| Aug 21, 2026 | $57.81 | $58.565 | $57.50 | $58.22 | 368.58K |
| Aug 20, 2026 | $58.08 | $58.68 | $57.44 | $57.76 | 439.17K |
| Aug 19, 2026 | $56.84 | $59.03 | $56.625 | $58.40 | 476.56K |
| Aug 18, 2026 | $55.10 | $57.00 | $55.10 | $56.39 | 565.38K |
| Aug 17, 2026 | $54.60 | $55.4885 | $54.17 | $54.43 | 427.74K |
| Aug 14, 2026 | $55.99 | $56.21 | $54.87 | $55.28 | 390.57K |
| Aug 13, 2026 | $54.60 | $56.10 | $54.50 | $56.06 | 665.84K |
| Aug 12, 2026 | $53.83 | $54.745 | $53.425 | $54.44 | 725.36K |
| Aug 11, 2026 | $55.22 | $55.3035 | $53.59 | $54.19 | 845.65K |
| Aug 10, 2026 | $58.55 | $58.84 | $55.18 | $55.30 | 925.26K |
| Aug 7, 2026 | $59.43 | $61.705 | $59.01 | $59.19 | 1.38M |
| Aug 6, 2026 | $57.90 | $59.1682 | $54.16 | $58.33 | 1.19M |
| Aug 5, 2026 | $63.78 | $63.805 | $62.3601 | $63.15 | 516.02K |
| Aug 4, 2026 | $61.32 | $63.33 | $61.075 | $63.33 | 583.2K |
| Aug 3, 2026 | $61.24 | $62.36 | $61.24 | $62.21 | 613.13K |
| Jul 31, 2026 | $60.02 | $60.74 | $59.545 | $60.25 | 578.13K |
| Jul 30, 2026 | $61.72 | $61.985 | $59.78 | $60.64 | 516.56K |
The latest Smart Investors Daily articles mentioning MMS.
MMS research
Company profile and research snapshot.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 2, 2025 | Raymond James | Outperform | — |
| Jan 3, 2024 | Raymond James | Market Perform | — |
| Aug 18, 2023 | Stifel | Buy | — |
| Feb 9, 2023 | Raymond James | Outperform | — |
| May 6, 2022 | Raymond James | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 17, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Yahoo · Aug 12, 2026
Maximus trades at a deep earnings discount, but federal procurement delays and weak award conversion cloud the timing of a recovery.
Yahoo · Aug 12, 2026
Maximus faces an earnings reset as paused VA incentives cut profit and cash-flow guidance, testing whether service and tech gains can rebuild momentum.
ChartMill · Aug 11, 2026
MAXIMUS (MMS) passes the Decent Value screen: cheap valuation, solid profitability, manageable debt, and steady growth—minus value trap risk.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MMS.
